Patents by Inventor Christine Brender Read

Christine Brender Read has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids encoding antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
    Patent number: 11858992
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: January 2, 2024
    Assignee: NOVO NORDISK A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • METHODS OF TREATING AUTOIMMUNE DISEASE OR CHRONIC INFLAMMATION WITH ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1)
    Publication number: 20210253697
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: February 1, 2021
    Publication date: August 19, 2021
    Inventors: Vibeke Westphal STENNICKE, Christine Brender READ, Susanne Nedergaard GRELL, Charlotte WIBERG, Rune SALBO, Anette HENRIKSEN, Soeren PADKJAER
  • Methods of treating autoimmune disease or chronic inflammation wtih antibodies that bind peptidoglycan recognition protein 1
    Patent number: 10906965
    Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 2, 2021
    Assignee: NOVO NORDISK A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Joseph Leon Kuijper, Xiaoting Tang, Mark Heipel, Siv Annegrethe Hjorth
  • Methods of treating autoimmune disease or chronic inflammation with antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
    Patent number: 10906975
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: February 2, 2021
    Assignee: NOVO NORDISK A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1)
    Publication number: 20190194321
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: December 4, 2018
    Publication date: June 27, 2019
    Applicant: Novo Nordisk A/S
    Inventors: Vibeke Westphal STENNICKE, Christine Brender READ, Susanne Nedergaard GRELL, Charlotte WIBERG, Rune SALBO, Anette HENRIKSEN, Soeren PADKJAER
  • ANTIBODIES THAT BIND PEPTIDOGLYCAN RECOGNITION PROTEIN 1
    Publication number: 20190119367
    Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
    Type: Application
    Filed: October 25, 2018
    Publication date: April 25, 2019
    Applicant: Novo Nordisk A/S
    Inventors: Vibeke Westphal STENNICKE, Christine Brender READ, Joseph Leon KUIJPER, Xiaoting TANG, Mark HEIPEL, Siv Annegrethe HJORTH
  • Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
    Patent number: 10189904
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: January 29, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • Antibodies that bind peptidoglycan recognition protein 1
    Patent number: 10150809
    Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: December 11, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Joseph Leon Kuijper, Xiaoting Tang, Mark Heipel, Siv Annegrethe Hjorth
  • ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1)
    Publication number: 20180105590
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: December 8, 2016
    Publication date: April 19, 2018
    Inventors: Vibeke Westphal STENNICKE, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune SaIbo, Anette Henriksen, Soeren Padkjaer
  • ANTIBODIES THAT BIND PEPTIDOGLYCAN RECOGNITION PROTEIN 1
    Publication number: 20180016326
    Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
    Type: Application
    Filed: April 10, 2017
    Publication date: January 18, 2018
    Inventors: Vibeke Westphal STENNICKE, Christine Brender Read, Joseph Leon Kuijper, Xiaoting Tang, Mark Heipel, Siv Annegrethe Hjorth
  • ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1)
    Publication number: 20170190775
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: December 8, 2016
    Publication date: July 6, 2017
    Inventors: Vibeke Westphal STENNICKE, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune SaIbo, Anette Henriksen, Soeren Padkjaer
  • Antibodies that bind peptidoglycan recognition protein 1
    Patent number: 9663568
    Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: May 30, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Joseph Leon Kuijper, Xiaoting Tang, Mark Heipel, Siv Annegrethe Hjorth
  • Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
    Patent number: 9550830
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: January 24, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • Antibodies that Bind and Block Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1)
    Publication number: 20150274825
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: February 26, 2015
    Publication date: October 1, 2015
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
    Patent number: 9000127
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: April 7, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • Antibodies That Bind Peptidoglycan Recognition Protein 1
    Publication number: 20150018528
    Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
    Type: Application
    Filed: November 30, 2012
    Publication date: January 15, 2015
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Joe Kuijper, Xiaoting Tang, Mark Heipel, Siv Annegrethe Hjorth
  • ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1)
    Publication number: 20130309239
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: July 30, 2013
    Publication date: November 21, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer